Devulapally, R. CV

*

Rammohan Devulapally, Ph.D.

**** ******* ****** **** # *** Phone: 650-***-**** Coppell, TX-75019

adfpet@r.postjobfree.com

https://www.linkedin.com/in/rammohandevulapally

https://scholar.google.com/citations?user=xACEyz8AAAAJ&hl=en SUMMARY

I am an innovative and critical thinking scientist with extensive research and strong technical expertise in gene delivery, non-viral delivery, nanoparticle development, CRISPR/Cas, mRNA, p-DNA, sense, and antisense microRNA, oligonucleotides, siRNAs delivery, lipid synthesis, lipid nanoparticles, liposomes, polymer nanoparticles, bioconjugation chemistry, targeted peptides, molecular biology, and molecular imaging as evidenced by over 20 high impact peer-reviewed publications, and many international conference presentations. I am currently working in ReCode Therapeutics, Inc. Before Joining ReCode, I was a research scientist at the Canary Center at Stanford for Cancer Early Detection and Molecular Imaging Program (MIPS) in the Department of Radiology at Stanford University Medical School. I have extensive knowledge and experience in the multidisciplinary fields of chemistry, nanomedicine, and biology. I have successful project management experience and experience in mentoring junior scientists. I am a self-motivated scientist looking for new opportunities in the industry in a fast face environment. UNITED STATES VISA STATUS: Permanent resident - green card holder (EB1A - Alien of Extraordinary Ability) WORK EXPERIENCE

Senior Scientist, R&D, Drug Delivery – Formulation Development at ReCode Therapeutics, Inc, Dallas, Texas - Nov 2017 to Present.

My work involves:

1) Advancing mRNA-mediated protein replacement and tRNA Nano Corrector therapies for cystic fibrosis and primary ciliary dyskinesia.

2) Developing proprietary non-viral lipid nanoparticle delivery platform for organ-specific delivery of RNA therapies and gene editing components.

3) Design, synthesis, and development of lipid nanoparticle systems for the delivery of different mRNAs

(CRISPR/Cas, CFTR mRNA, mCherry mRNA, Fluc mRNA, etc), and small RNAs (tRNAs, sgRNAs, etc). 4) Development of mRNA and tRNA loaded lipid nanoparticles for pulmonary and nasal routes of delivery. 5) Collaborative R&D work with other companies.

6) Initiate and manage projects with external CROs and CMOs (Avecia, Charles River Laboratories, ITR labs Canada, Precision Nanosystems).

Achievements:

1) Successfully developed ReCode first IND candidate RCT223 lipid Nano Corrector for CFTR mutations. 2) Successfully developed ReCode organ-specific lipid nanoparticle systems for mRNA and small RNAs delivery. 3) Successfully optimized, a process developed, and scaled-up the RCT223 and other mRNA LNPs from small scale to largescale using Precision NanoSystems Benchtop and Blaze Microfluidic Nano assemblers and purified using GE's Akta Flux tangential flow filtration (TFF) system. 4) Successfully developed mRNA and tRNA loaded lipid nanoparticles for pulmonary and nasal routes of delivery. 5) Successfully developed protocols and SOPs.

Resulted in publications/Conference presentations: 4 conference presentations. Research Scientist, Stanford University - Palo Alto, CA - June 2015 to Nov 2017 Postdoctoral research fellow, Stanford University - Palo Alto, CA - June 2012 to May 2015 My work involves: Drug delivery, gene delivery, nanoparticle development, synthetic organic chemistry, solid-phase peptide synthesis, bioconjugation chemistry, molecular imaging, animal imaging, cell, and molecular biology. 1) Small molecules synthesis, peptides synthesis; 2) Conjugation of peptides with bio-polymers; 3) Conjugation of biotin, and different fluorophores (Cy3, Cy5, Fluorescein, IR800, etc) to peptides, proteins, Ab’s and bio-polymer; 4) Synthesis and formulation of microRNA and drugs encapsulated polymer nanoparticles for cancer therapy; 5) Molecular imaging of fluorescent dyes and peptides conjugated polymer nanoparticles; 6) Synthesis and formulation Devulapally, R. CV

2

of cationic polymer nanoparticles for DNA delivery. 7. Synthesis of targeted peptides as molecular sensors for imaging histone methylation as a biomarker for early cancer detection, 8) Mammalian cell culture work, transfection, transduction, bacterial transformation and isolation of plasmid DNA, RNA isolation, agarose gel electrophoresis, protein isolation and purification, gel filtration, SDS-PAGE gel electrophoresis, western blot analysis, immunoassays, flow cytometry (FACS), bioluminescence, and fluorescence imaging in cells and mice. Resulted in publications: 15 peer-reviewed journal articles and 19 conference presentations. Postdoctoral research associate, Texas A&M University - September 2010 to May 2012 My work involves: Organic synthesis (Suzuki-Miyaura cross-coupling reaction of organotrifluoroborats). Resulted in publications: 2 peer-reviewed journal articles and 3 conference presentations. Postdoctoral fellow, Chung Yuan Christian University - August 2009 to August 2010 My work involves: Organic Synthesis and Photochemistry. Resulted in publications: 1 peer-reviewed journal articles Graduate Research Assistant, National Chung Cheng University - September 2004 to June 2009 My work involves: Organic synthesis and total synthesis of natural products. Resulted in publications: 3 peer-reviewed journal articles and 3 conference presentations. Research Assistant, Chemical Genomics National Research Laboratory, Seoul, Korea – Feb. 2004 to Aug. 2004 My work involves: Medicinal Chemistry.

Resulted in publications: 1 conference paper.

Research Chemist, Dr. Reddy's Laboratories Ltd - Hyderabad, Telangana, India - 2003 to 2004 My work involves: Medicinal Chemistry.

EDUCATION

Doctor of Philosophy (Ph.D.) in Synthetic Organic Chemistry, 2009 National Chung Cheng University, Chiayi, Taiwan

Master of Science in Organic & Medicinal Chemistry, 2002 Bachelor of Science in Chemistry & Biology, 2000

Kakatiya University, Warangal, Telangana, India

SKILLS

Chemistry and Nanoparticle skills (major): Nanoparticle development, nanoparticle optimization, nanoparticle formulation, lipid synthesis, lipid nanoparticles, nanomedicine, drug delivery, gene delivery, targeted delivery, CRISPR/Cas, oligonucleotides, mRNA, sense and antisense miRNA, oligonucleotides, siRNA, tRNA, sgRNA, Chemistry, Manufacturing, and Controls (CMC), liposomes, polymer nanoparticles, dendrimers, PLGA, microfluidic nanoparticle formulation, nanoparticle process development, scale-up, diafiltration, lyophilization, freeze/thaw, cryopreservation, aerosolization of nanoparticles, organic synthesis, sterile filtration, bioconjugation chemistry, biomolecules (biotin, peptides, proteins, antibodies) and fluorescent dyes labeling techniques, solid-phase peptide synthesis, polymer conjugation, and purification, antibody, size exclusion chromatography (SEC), oligonucleotides, gel filtration, and dialysis.

Cell and molecular biology skills: Mammalian cell culture work, Flow cytometry (FACS), transfection, transduction, BSL2 viral vectors, bacterial transformation and isolation of plasmid DNA, mRNA isolation, Ribogreen assay, agarose gel electrophoresis, protein isolation, protein purification, antibody, affinity purification, gel filtration, SDS-PAGE gel electrophoresis, immunoassays, western blot analysis, MTT assay, bioluminescence, fluorescence imaging, animal

(mice) handling and imaging.

Instrumentation skills: Malvern Dynamic Light Scattering (DLS) Zetasizer, Precision NanoSystems Benchtop, and Blaze Microfluidic Nano assemblers, GE's Akta Flux tangential flow filtration (TFF) system. GC-MS, MALDI-TOF-MS

(AB Sciex 5800 TOF/TOF system), HPLC/UPLC, FPLC, CS-Bio peptide synthesizer, microplate reader, Nanodrop, NMR (Varian Gemini 200 MHz, Bruker Avance 300 MHz, and 400 MHz, Agilent 400 MHz), UV-Vis, FT-IR, wide-field fluorescence microscopy, Bio-Rad Molecular Imager® Gel Doc™ XR documentation system, IVIS Spectrum, Bruker Xtreme molecular imaging system, Spectral Instruments Imaging (Lago), Beckman Coulter liquid scintillation counter. Devulapally, R. CV

3

AWARDS

Outstanding Reviewer, International Journal of Pharmaceutics, 2017, and Journal of Controlled Release, 2017 Outstanding Reviewer, Tetrahedron Letters, 2016

Postdoctoral fellowship, Stanford University School of Medicine, June 2012 Postdoctoral fellowship, Texas A&M University at Qatar, September 2010 National Science Council (NSC) Taiwan, Postdoctoral fellowship, August 2009 PROFESSIONAL AFFILIATIONS

Member, American Chemical Society (2010), World Molecular Imaging Society (2013) JOURNALS PEER REVIEWER

Clinical Cancer Research (AACR), Molecular Cancer Therapeutics (AACR), Journal of Controlled Release, International Journal of Pharmaceutics, Journal of Organic Chemistry, Tetrahedron, Tetrahedron Letters, Bioorganic

& Medicinal Chemistry Letters, European Journal of Medicinal Chemistry, World Molecular Imaging Congress, International Journal of Nanomedicine, Drug Design Development, and Therapy, Biochemical pharmacology, Journal of Cellular Physiology, Letters in Drug Design & Discovery, etc. EDITORIAL MEMBERSHIPS

Consulting editor, Drug Design, Development, and Therapy. ADDITIONAL INFORMATION

COMPLETE LIST OF PUBLICATIONS AND RESEARCH PROJECTS LIST OF PUBLICATIONS:

1. Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo. Wischhusen, J.; Chowdhury, S. M.; Lee, T.; Wang, H.; Bachawal, S. V.; Devulapally, R.; Afjei, R.; Sukumar, U. K.; Paulmurugan, R. Journal of Controlled Release 2020, 321, 272- 284

2. Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. Kimura, R. H.; Wang, L.; Shen. B.; Huo. L.; Tummers. W.; Filipp, F. V.; Guo, H. H.; Haywood, T.; Abou- Elkacem, L.; Baratto, L.; Habte, F.; Devulapally, R.; Gambhir S. S. Nature Communications 2019, Oct 14, 10(1):4673.

3. Characterization of the Nanocorrector, RCT223: A modified transfer RNA-nanoparticle system that restores CFTR function in primary HBE cells derived from cystic fibrosis patients with nonsense mutations. R Devulapally, ML Coquelin, RJ Bridges, PJ Thomas, D Siegwart, AE Johnson, MJ Torres Pediatric Pulmonology, 2019, 54, S217-S217.

4. The RCT223 Nanocorrector restores function in primary HBE cells derived from cystic fibrosis patients with nonsense mutations. MJ Torres, R Devulapally, M Coquelin, J Miller, L Millen, L De Keyzer, Z Cai, Q Li, J Wangen, J Harrington, Patel A Thakerar, C Oliveira, DN Sheppard, A Feranchak, R Green, H Bihler, M Mense, RJ Bridges, PJ Thomas, D Siegwart, AE Johnson. Pediatric Pulmonology, 2019, 54, S218-S218. 5. Lipid nanoparticle delivery of mRNA to fully differentiated, patient-derived bronchial epithelial cells. ML Coquelin, R Devulapally, L Farbiak, L Johnson, RJ Bridges, PJ Thomas, D Siegwart, MJ Torres. Pediatric Pulmonology, 2019, 54, S217-S217.

6. Longitudinal assessment of ultrasound-guided complementary microRNA therapy of hepatocellular carcinoma. Chowdhury, S. M.; Lee, T.; Bachawal, S. V.; Devulapally, R.; Abou-Elkacem, L.; Yeung, T. A.; Wischhusen, J.; Tian, L.; Dahl, J.; Paulmurugan, P.; Willmann, J. K. Journal of Controlled Release 2018, 281, 19-28.

Devulapally, R. CV

4

7. Ultrasound-Guided Delivery of TK-NTR-Dual Therapeutic Genes by PEGylated-PLGA/PEI NPs for Enhanced TNBC Therapy. Devulapally, R.; Sekar, T. V.; Lee, T.; Willmann. J. K.; Paulmurugan, R. Nanomedicine

(London) 2018, 13,1051-1066.

8. Targeted nanoparticle delivery of therapeutic antisense microRNAs sensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and a mouse model. Malhotra, M.; Sekar, T. V.; Ananta, J. S.; Devulapally, R.; Afjei, R.; Abdelsalam.; Paulmurugan, R.; Massoud, T. F. Oncotarget 2018, 9, 21478– 21494.

9. Gemcitabine and anti-microRNA co-encapsulated PLGA-PEG polymer nanoparticles for hepatocellular carcinoma therapy. Devulapally, R.; Foygel, K.; Sekar, T. V.; Willmann, J. K.; Paulmurugan, R. ACS Applied Materials & Interfaces 2016, 8, 33412–33422.

10. A molecular imaging biosensor monitors p53 sumoylation in cells and living mice. Sekar, T. V.; Foygel, K.; Devulapally, R.; Kumar, V.; Malhotra, S.; Massoud, T. F.; Paulmurugan, R. Analytical Chemistry 2016, 88, 11420–11428.

11. Hepatocellular Carcinoma Treatment by Ultrasound-Guided Delivery of Two Complementary microRNAs: miRNA-122 and antimiR-21. Chowdhury, S. M.; Wang, T.-Y.; Bachawal, S.; Devulapally, R.; Choe, J. W.; Elkacem, A. L.; Yakub, B. K.; Wang, D.; Paulmurugan, R.; Willmann, J. K. Journal of Controlled Release 2016, 238, 272-280.

12. Orlistat and Antisense-microRNA loaded PLGA-PEG nanoparticles for Enhanced Triple Negative Breast Cancer Therapy. Bhargava-Shah, A.; Foygel, K.; Devulapally, R.; Paulmurugan, R. Nanomedicine

(London) 2016, 11, 235-247.

13. Folate receptor targeted polymeric micellar nanocarriers for the delivery of orlistat as a repurposed drug against triple-negative breast cancer. Paulmurugan, R.; Bhethanabotla, R.; Mishra, K.; Devulapally, R.; Foygel, K.; Sekar, T. V.; Ananta, J. S.; Massoud, T. F.; Joy, A. Molecular cancer therapeutics, 2016, 15, 221-231 (Research featured on the cover of the journal). 14. Formulation of anti-miR-21 and 4-hydroxytamoxyfen co-loaded biodegradable polymer nanoparticles and its anti-proliferative effect on breast cancer cells. Devulapally, R.; Sekar, T. V.; Paulmurugan, R. Molecular Pharmaceutics, 2015, 12, 2080-2092.

15. Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy. Devulapally, R.; Narayana M Sekar, N. M.; Sekar, T. V.; Foyel, K.; and Massoud, T. F.; Willmann, J. K.; Paulmurugan, R. ACS Nano, 2015, 9, 2290-2302. 16. Ultrasound-guided Delivery of microRNA Containing Nanoparticles into Cancer. T. Y. Wang, J. W. Choe, Pu, R. Devulapally, Bachawal, S.; Machtaler, S.; Chowdhury, S.M.; Luong, R.; Tian, L.; Khuri-Yakub, P. T.; Rao, J-H.; Paulmurugan, R.; Willmann, J. K. Journal of Controlled Release, 2015, 203, 99-108. 17. Degron Protease Blockade Sensor to Image Epigenetic Histone Protein Methylation in Cells and Living Animals. Sekar, T. V.; Foyel, K.; Devulapally, R.; Paulmurugan, R. ACS Chem. Biol., 2015, 10, 165–174. 18. Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Devulapally, R.; Paulmurugan, R.* WIREs Nanomed Nanobiotechnol 2014, 6:40–60. 19. Suzuki-Miyaura Cross-Coupling of Potassium Trifluoro(N-Methylheteroaryl)borates with Aryl and Heteroaryl Halides. Molander, G. A.; Ryu, D. W.; Hosseini-Sarvari, M.; Devulapally, R.; Seapy, D. G. The Journal of Organic Chemistry, 2013, 78, 6648-6656. Highlighted in ChemInform, 2013, Vol. 44, Issue 48. Devulapally, R. CV

5

20. Synthesis and cross-coupling reactions of potassium imidomethyltrifluoroborates with aryl chlorides. Devulapally, R.; Nicolas, N.; Molander G. A.; Seapy, D. G. Tetrahedron Lett. 2012, 53, 1051-1055. Highlighted in ChemInform, 2012, Vol. 43, Issue 25. 21. The first total synthesis of zenkequinone B. Devulapally, R.; Hon, Y-S. Tetrahedron Lett. 2011, 52, 3183- 3185.

22. Efficient syntheses of 3H-azuleno[8,1-cd]pyridazines and their thermal and photochemical reactions. Wu, C- P.; Devulapally, R.; Li, T-C.; Ku, C-K.; Chung, H-C. Tetrahedron Lett. 2010, 51, 4819–4822. Highlighted in ChemInform, 2011, Vol. 42, Issue 01.

23. A concise methodology for the synthesis of 2-tetralone by TiCl4 promoted cyclization of 4-aryl-2- hydroxybutanal diethyl acetal. Hon Y-S.; Devulapally, R. Tetrahedron Lett. 2009, 50, 5713–5715. Highlighted in ChemInform, 2010, Vol. 41, Issue 02. 24. TiCl4-promoted intramolecular cyclization of 4-methoxy-5-arylethyl-1,3-dioxolan-2-ones: an expedient method to prepare 2-tetralones. Hon Y-S.; Devulapally, R. Tetrahedron Lett. 2009, 50, 2831–2834. Highlighted in ChemInform, 2009, Vol. 40, Issue 38. List of papers presented in Conferences:

1. The RCT223 NanoCorrector restores function in primary hBE cells derived from cystic fibrosis patients with nonsense mutations. Torres, MJ; Devulapally, R; Coquelin, M; Miller, JB; Peters-Hall, JR; Millen L; De Keyzer, L; Abid, S; Cai, Z; Li, Q; Wangen, J; Harrington, J; Patel, A; Oliveira, C; Randell, SH; Sheppard, DN; Feranchak, AP; Green, R; Bihler, H; Mense, M; Bridges, RJ; Jain, R; Shay, JW; Thomas, PJ; Siegwart, DJ; Johnson, AE. Tides: Oligonucleotide and Peptide Therapeutics, May 20-23, 2019, San Diego, CA. 2. Ultrasound-Mediated Delivery of microRNA-Loaded Nanoparticles Modulates Immune Responses in Subcutaneous Murine Hepa1-6 Hepatocellular Carcinoma. Wischhusen, J.; Sayan Mullick Chowdhury, S. M.; Lee, T.; Bachawal, S.; Devulapally, R.; Padilla, F.; Willmann, J. K.; Paulmurugan, R. World Molecular Imaging Congress (WMIC) 2018, Sept. 12-15, 2018, Seattle, WA, United States. 3. Targeted nanoparticle delivery of therapeutic antimiR-21 and antimiR-10b presensitizes glioblastoma to lower effective doses of temozolomide in cells and xenografts. Massoud, T. F, Malhotra, M, Sekar, T. V.; Devulapally, R.; Afjei, R.; Paulmurugan, R.; Society for Neuro-Oncology's 22nd Annual Scientific Meeting. November 16-19, 2017, San Francisco, California

4. Ultrasound Image-Guided Targeted Delivery of Dual-Therapeutic Gene-PLGA-PEG/PEI Nano complex for Improved Cancer Gene Therapy In Vivo. Devulapally, R.; Lee, T.; Sekar, T. V.; Willmann. J. K.; Paulmurugan, R. World Molecular Imaging Congress (WMIC) 2017, Sept. 13-16, 2017, Philadelphia, PA, United States.

5. Ultrasound and Microbubble Mediated Modulation of Drug Resistance in Hepatocellular Carcinoma using Complementary MicroRNAs. Chowdhury, S. M.; Lee, T.; Bachawal, S.; Elkacem, A. L; Devulapally, R.; Paulmurugan, R.; Willmann. J. K. WMIC 2017, Sept. 13-16, 2017, Philadelphia, PA, United States. 6. Targeted delivery of antimiR-21 and antimiR-10b using c-RGD-functionalized PLGA nanoparticles chemosensitizes glioblastoma cells and xenografts to temozolomide. Malhotra, M, Sekar, T. V.; Devulapally, R.; Afjei, R.; Paulmurugan, R.; Massoud, T. F. WMIC 2017, Sept. 13-16, 2017, Philadelphia, PA, United States.

7. Longitudinal Assessment of Ultrasound-guided Complementary miRNA (miRNA-122/AntimiR-21) Therapy for Hepatocellular Carcinoma. Chowdhury, S. M.; Lee, T.; Bachawal, S.; Elkacem, A. L; Devulapally, R.; Paulmurugan, R.; Willmann. J. K. WMIC 2017, Sept. 13-16, 2017, Philadelphia, PA, United States. Devulapally, R. CV

6

8. Imaging guided Therapeutic Modulation of Hepatocellular Carcinoma using Two Complementary MicroRNAs. Chowdhury, S. M.; Wang, T. –Y.; Bachawal, S.; Devulapally, R.; Paulmurugan, R.; Willmann. J. K. Controlled Release Society (CRS) annual meeting, July 17-20, 2016, Seattle, Washington, USA. 9. Nanoparticle facilitated dual therapeutic gene delivery in living animals for enhanced cancer gene therapy and imaging. Devulapally, R.; Sekar, T. V.; Paulmurugan, R. WMIC 2016, Sept. 7-10, 2016, New York, NY, United States.

10. Ultrasound Guided Therapeutic Modulation of Hepatocellular Carcinoma using Complementary microRNAs Chowdhury, S. M.; Wang, T. –Y.; Bachawal, S.; Elkacem, A. L; Devulapally, R.; Paulmurugan, R.; Willmann. J. K. Radiology Society of North America (RSNA) annual meeting, Nov 27 - Dec 2, 2016, Chicago, United States.

11. Ultrasound-guided complementary miRNA/antimiR therapy for Hepatocellular Carcinoma. Chowdhury, S. M.; Wang, T. –Y.; Bachawal, S.; Devulapally, R.; Paulmurugan, R.; Willmann. J. K. WMIC 2016, Sept. 7-10, 2016, New York, NY, United States.

12. Molecular imaging of polymer nanoparticles facilitated multi-microRNA therapy for triple-negative breast cancer in small animal model. Devulapally, R.; Sekar, T. V.; Foyel, K.; Massoud, T. F.; Willmann, J. K.; Paulmurugan, R. WMIC 2015, Sept. 2-5, 2015, Honolulu, Hawaii, United States. 13. Antiproliferative effect of microRNA and 4-hydroxytamoxifen coloaded urokinase plasminogen activator receptor (uPAR) targeted polymer nanoparticles in ER+ breast cancer cells. Devulapally, R.; Foyel, K.; Sekar, T. V.; Paulmurugan, R. WMIC 2015, Sept. 2-5, 2015, Honolulu, Hawaii, United States. 14. Synthesis of gemcitabine and anti-miR-21 coloaded polymer nanoparticles and its cytotoxicity evaluation in hepatocellular carcinoma cells. Devulapally, R.; Sekar, T. V.; Paulmurugan, R. WMIC 2015, Sept. 2-5, 2015, Honolulu, Hawaii, United States.

15. [18F]FP-R01-MG-F2, A Radiofluorinated Cystine Knot PET Tracer For Pancreatic Cancer Detection. Kimura, R.; Shen, B.; Witney, T. H.; Devulapally, R.; Filipp, F.; Ilovich, O.; Natarajan, A.; Cheng, Z.; Chin, F.; Gambhir, S. S. WMIC 2015, Sept. 2-5, 2015, Honolulu, Hawaii, United States 16. Ultrasound and Microbubble Mediated Therapeutic Modulation of Hepatocellular Carcinoma using Two Complementary MicroRNAs. Chowdhury, S. M.; Wang, T. –Y.; Bachawal, S.; Devulapally, R.; Paulmurugan, R.; Willmann. J. K. WMIC 2015, Sept. 2-5, 2015, Honolulu, Hawaii, United States. 17. Orthotopic Human Hepatocellular Carcinoma Model in Rabbits for Combined Ultrasound-Guided and Transcatheter Hepatic Arterial Drug Delivery. Bachawal, S.; Wang, D.; Wang, T. -Y.; Chowdhury, S. M.; Devulapally, R.; Felt, S.; Paulmurugan, R.; Willmann, J. K. WMIC 2015, Sept. 2-5, 2015, Honolulu, Hawaii, United States.

18. Spatial distribution and intracellular delivery of therapeutic microRNA loaded nanocarriers in tumors using ultrasound induced microbubble cavitation. Wang, T. -Y.; Chowdhury, S. M.; Bachawal, S.; Choe, J. W.; Devulapally, R.; Pu, K.; Abou-Elkacem, L.; Khuri-Yakub, A. B.; Rao, J.; Paulmurugan, R.; Willmann. J. K. WMIC 2015, Sept. 2-5, 2015, Honolulu, Hawaii, United States. 19. Imaging ligand induced Estrogen receptor (ER)/Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) interaction in environmental estrogen induced carcinogenesis. R. Paulmurugan, K. M. Ramkumar, K. Foygel, T.V. Sekar, R. Devulappally. WMIC 2014, Sept. 17-20, 2014, Seoul, Korea. 20. Effects of Ultrasound Parameters on Cavitation-Assisted Delivery of PLGA-PEG Nanoparticles into Tumors: Phantom Study and Preliminary in vivo Results. T. Y. Wang, J. W. Choe, S. Machtaler, R. Devulapally, P. T. Khuri-Yakub, R. Paulmurugan, and J. K. Willmann, RSNA annual meeting, Dec. 1-6, 2013, Chicago, United States.

Devulapally, R. CV

7

21. Anti-Proliferative Effect of 4-Hydroxytamoxifen Loaded PLGA-b-PEG Nanoparticles in Human Breast Cancer Cell lines Expressing Different Levels of Her2 Receptor. R. Devulapally, T.V. Sekar, R. Paulmurugan. WMIC 2013, Sept. 18-21, 2013, Savannah, Georgia, United States. 22. Optimizing acoustic cavitation for ultrasound-microbubble-mediated delivery of PLGA nanoparticles into tumors: phantom study and preliminary in vivo results. T. Y. Wang, J. W. Choe, S. Machtaler, R. Devulapally, P. T. Khuri-Yakub, R. Paulmurugan, and J. K. Willmann. WMIC 2013, Sept. 18-21, 2013, Savannah, Georgia, United States.

23. Synthesis of potassium heteroarylmethyltrifluoroborates and their use in Suzuki-Miyaura cross-coupling reactions. Ryu, D-W.; Devulapally, R.; Molander, G. A.; Seapy, D.G. 244th American Chemical Society

(ACS) National meeting, Aug 19-23, 2012, Philadelphia, PA, United States. 24. Synthesis and Suzuki-Miyaura coupling reactions of potassium pyrrolomethyltrifluoroborate with aryl chlorides. Devulapally, R.; Ryu, D-W.; Molander, G. A.; Seapy, D. G. The French-American Chemical Society (FACS XIV) Conference, June 10-14, 2012, Nantasket Beach Resort, Hull, MA, United States. 25. Synthesis of imidomethyltrifluoroborates and their use in Suzuki-Miyaura cross coupling reactions with aryl chlorides. Gary A. Molander, Devulapally, R. Fleury-Bregeot, N.; Seapy, D. G. American Chemical Society 42nd National Organic Symposium (NOS) June 5-9, 2011, Princeton University, Princeton, NJ, United States.

26. 4-Methoxy-1,3-dioxolan-2-ones: An useful moiety in organic synthesis. Hon, Y-S.; Devulapally, R.; Kao, C- Y.; and Hsieh, C-H. "2008 Annual Meeting of Chemical Society Located in Taipei,” Dec 5-7, 2008 at National Changhua University of Education, Changhua, Taiwan. 27. The formation of 4-methoxy-1,3-dioxolan-2-ones from α-carbonato-aldehyde and its applications in 2- tetralone formation. Devulapally, R.; Hon, Y-S* The 9th International Symposium on Organic Reactions

(ISOR-2008/Chiayi), Nov. 20-23, 2008, Chiayi, Taiwan. 28. A new, efficient and versatile methodology for the synthesis of 2-tetralones. Devulapally, R.; Hon, Y-S.;* Chen, C-H. 2nd International Conference of Cutting Edge Organic Chemistry in Asia, Sept. 1-5, 2007, Busan, Korea.

29. Development of a new Ca2+/calmodulin antagonist and its antitumor activity against colorectal cancer cells. Shim, J-S.; Lee, J.; Devulapally, R.; Kim, K. N.; Kwon, H, J. 62nd Korean Society of Biochemistry and Molecular Biology Annual Meeting (62nd KSBMB Annual meeting 2005), Seoul, South Korea, May 19-20, 2005.

List of conferences attended/participated

30. 14th IUPAC Conference on Polymers and Organic Chemistry (POC 2012), Jan 6-9, 2012, Doha, Qatar. 31. 11th International Chemical Conference, (ICCT 2007) Dec 13-16, 2007, Hsinchu, Taiwan 32. 1st India-Taiwan Conference on Frontiers of Organic Chemistry, Jan 8-10, 2007, NTHU, Hsinchu, Taiwan. 33. 1st International Conference on Cutting-Edge Organic Chemistry in Asia Post-Conference (ICCEOCA-1), Oct 21-24, 2006, Hsinchu, Taiwan.

34. 10th International Chemical Conference, (ICCT 2005) Oct 28-30, 2005, Hsinchu, Taiwan. 35. 61st Korean Society for Biochemistry and Molecular Biology Annual Meeting, May 27-28, 2004, Seoul, Korea. 36. 93rd Korean Chemical Society National Meeting, April 22-23, 2004, Seoul, Korea Academic Research Projects:

NIH 1R01 04/01/2017- 11/07/2019

Principal Investigators: Juergen Willmann and Ramasamy Paulmurugan Title: Therapeutic miRNA modulation of hepatocellular carcinoma using ultrasound guided drug delivery Goal: The goal of this project was to develop ultrasound-guided delivery of anti-miR-21 and miR-122 loaded PLGA- PEG nanoparticles for the hepatocellular carcinoma therapy. Devulapally, R. CV

8

Role: Research scientist

NIH R21 06/01/2016 - 11/07/2019

Principal Investigators: Juergen Willmann and Ramasamy Paulmurugan Title: 3D Passive Cavitation Imaging-Guided Therapeutic Delivery of MicroRNA into Cancer Goal: The goal of this grant was to develop a novel genetic reprogramming approach to effectively treating HCC with reduced recurrence risk by delivering therapeutic microRNAs using an image- guided ultrasound and microbubble facilitated drug delivery platform.

Role: Research scientist

NIH R21 04/11/2014 – 03/31/2016

Principal Investigators: Tarik Massoud and Ramasamy Paulmurugan Title: Druggable p53 misfolding in cancer: A novel in vivo molecular imaging biosensor Role: Postdoctoral research fellow and research scientist NIH R01 06/01/2012 – 03/31/2016

Principal Investigator: Ramasamy Paulmurugan

Title: Molecular Sensors for Imaging Histone Methylations in Living Animals Goal: The goal of this grant was to develop in vivo imaging methods to study histone methylation specifically in N-tail lysine and arginine.

Role: Postdoctoral research fellow and research scientist CCNE-Pilot Project 08/01/2014 – 07/31/2015

Principal Investigator: Ramasamy Paulmurugan

Title: To develop high-sensitive nanoplasmonic sensor for simultaneous quantitation of chromodomains recruitment to two-histone lysine methylation marks (H3K9me3 and H3K4me3) Goal: Develop highly sensitive localized nanoplasmonic sensor for measuring the recruitment of chromodomains from royal family structural fold to methylated histone marks in H3 and H4 proteins Role: Postdoctoral research fellow

Qatar National Research Fund (QNRF), National Priorities Research Program (NPRP) 9/2010-5/2012 Principal Investigators: Dave Seapy and Gary Molander Project: Acyltrifluoroborates: Stable Acyl Anion Equivalents Goal: Development of Suzuki-Miyaura cross-coupling reactions of organotrifluoroborates. Role: Postdoctoral research associate

National Science Council (NSC) Taiwan 08/2009-08/2010 Principal Investigator: Chun-Chen-Liao

Grant No.: NSC 98-2811-M-033-016, 99-2811-M-033-009 Project: I. Masked ortho-benzoquinones chemistry (MOBs) in organic synthesis; II. Efficient synthesis of 3H- azuleno[8,1-cd]pyridazines and their thermal and photo chemical reactions. Role: Postdoctoral fellow

Contact this candidate